Understanding the Battle for Universal Pharmacare in Canada; Comment on “Universal Pharmacare in Canada”

Publish Year: 1400
نوع سند: مقاله ژورنالی
زبان: English
View: 5

متن کامل این Paper منتشر نشده است و فقط به صورت چکیده یا چکیده مبسوط در پایگاه موجود می باشد.
توضیح: معمولا کلیه مقالاتی که کمتر از ۵ صفحه باشند در پایگاه سیویلیکا اصل Paper (فول تکست) محسوب نمی شوند و فقط کاربران عضو بدون کسر اعتبار می توانند فایل آنها را دریافت نمایند.

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_HPM-10-3_010

تاریخ نمایه سازی: 18 مرداد 1403

Abstract:

Drug coverage in Canada is a patchwork; an inequitable inefficient and unsustainable patchwork with no coherence or purpose. Some people think that we can solve the problem by adding more patches, but the core of the problem is that it is a patchwork. For the working population, access to medicines is still organized as privileges offered by employers to their employees. Universal pharmacare would not only provide better access to needed prescription drugs, but also eliminate waste, ensure value-for-money and help improve drug safety and appropriate prescribing. Opponents fear that a universal pharmacare plan would ration drugs, and impede drug access for some patients. However, these claims misunderstand the reality of drug coverage, pricing and access. Opponents propose, instead, to “fill the gap” of current drug coverage by implementing catastrophic coverage, which would serve commercial interests without maximizing health outcomes for the Canadian population. In spite of overwhelming evidence and consensus in the academic community in favour of universal pharmacare, the battle is far from over.

Authors

Marc-André Gagnon

School of Public Policy and Administration, Carleton University, Ottawa, ON, Canada

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Advisory Council for the Implementation of National Pharmacare. A Prescription ...
  • Hajizadeh M, Edmonds S. Universal pharmacare in Canada: a prescription ...
  • Lewis S. It won’t be easy: how to make universal ...
  • Morgan SG, Martin D, Gagnon MA, Mintzes B, Daw JR, ...
  • Canadian Institute for Health Information (CIHI). How Canada Compares: Results ...
  • OECD. Health at a Glance ۲۰۱۹: OECD Indicators. Paris: OECD ...
  • Gagnon MA. A Roadmap to a Rational Pharmacare Policy in ...
  • O'Brady S, Gagnon MA, Cassels A. Reforming private drug coverage ...
  • Face to Face in Drug Plan Management - Research results. ...
  • Canadian Agency for Drugs & Technologies in Health CADTH Canadian ...
  • Express Scripts Canada. Prescription Drug Trend Report. Express Script Canada; ...
  • Patented Medicine Prices Review Board (PMPRB). Annual Report ۲۰۱۷. Ottawa: ...
  • Advisory Council for the Implementation of National Pharmacare. Interim Report ...
  • In support of universal pharmacare. Pharmacare ۲۰۲۰ website. https://pharmacare۲۰۲۰.ca/our-letter ...
  • Morgan SG, Law M, Daw JR, Abraham L, Martin D. ...
  • Office of the Parliamentary Budget Officer. Federal Cost of a ...
  • GlaxoSmithKline's Patient group funding disclosure. https://ca.gsk.com/en-ca/responsibility/responsibility-reports-and-additional-data/patient-group-funding/best-medicines-coalition-bmc/ ...
  • Batt S. The Big Money Club: Revealing the Players and ...
  • Rawson NSB. National pharmacare in Canada: equality or equity, accessibility ...
  • Acri KML. The Unintended Consequences of National Pharmacare Programs: The ...
  • Sutherland G, Dinh T. Understanding the Gap: A Pan-Canadian Analysis ...
  • Canadian Pharmacists Association. A Prescription for a Healthier Canada; Rx: ...
  • Sun Life Financial. National Pharmacare: Getting it Right. Sun Life ...
  • Macdonald K. Employer-Sponsored Drug Plans Becoming Risky Business. Benefits Canada ...
  • Charbonneau M, Gagnon MA. Surviving niche busters: main strategies employed ...
  • Bourassa Forcier M, Noël F. Product listing agreements (PLAs): a ...
  • Olson M Jr. The Logic of Collective Action: Public Goods ...
  • Gagnon MA, Hébert G. The Economic Case for Universal Pharmacare. ...
  • نمایش کامل مراجع